Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.53 |
| ▸ | FEN1 | P39748 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12647390 | 0.80 | MEN1 (0.51) | PARP1HPGDMAPTALDH1A1POLB | |
| SCHEMBL3869644 | 0.79 | ERCC5 (0.56) | ERCC5FEN1PARP1HPGDMAPT | |
| SCHEMBL11074838 | 0.79 | GSK3B (0.53) | ERCC5FEN1HPGDMAPTALDH1A1 | |
| SCHEMBL1283 | 0.78 | TDP1 (0.52) | ERCC5FEN1HPGDMAPTALDH1A1 | |
| SCHEMBL2554619 | 0.77 | ERCC5 (0.57) | ERCC5FEN1PARP1HPGDMAPT | |
| SCHEMBL11753942 | 0.77 | ERCC5 (0.53) | ERCC5FEN1PARP1HPGDMAPT | |
| SCHEMBL24239347 | 0.76 | CES2 (0.56) | HPGDMAPTALDH1A1POLB | |
| SCHEMBL220453 | 0.76 | ERCC5 (0.49) | ERCC5FEN1PARP1HPGDMAPT | |
| SCHEMBL1711979 | 0.76 | ERCC5 (0.49) | ERCC5FEN1PARP1HPGDMAPT | |
| SCHEMBL11791699 | 0.76 | ERCC5 (0.76) | ERCC5FEN1PARP1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6888012-B2 | Reducing an alpha -haloketone compound by asymmetric hydrogen transfer in presence of a group 9 transition metal compound having a substituted or unsubstituted cyclopentadienyl group and an optically active diamine compound | AJINOMOTO CO., INC. (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20040082820-A1 | Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals | AJINOMOTO CO., INC. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1346972-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE HALOHYDRIN COMPOUND | Ajinomoto Co., Inc. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082820-A1 | Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals | DHPS, HDHD5, HYPK | ERCC5 4474/4885FEN1 4530/4885PARP1 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.